Endosseous implant

Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, characterized in that said surface has been treated with at least one organic compound corresponding to the general formula (I):

• A-[P(O)(OH)2]p (I),
• or a pharmaceutically acceptable derivative thereof, which preferably is an ester an amide or a salt thereof, wherein A means A1 or A2, and
• A1 is a residue of a linear, branched or cyclic, saturated or unsaturated, hydrocarbon residue with n carbon atoms, whereby said residue may be substituted by hydroxyl and/or carboxyl and optionally further interrupted by one or more oxygen and/or sulphur and/or nitrogen atoms, carrying p phosphonic acid groups, wherein n is a number from 1 to 70, preferably 1 to 40, preferably 1 to 22, and
• when n is 1 and p is 2:
• A is —CH2—, or
• when n is 1:
• p is 3 or 4, preferably 3, or
• when n is 2 to 10:
• p is 2, provided each phosphonic acid group or phosphonic acid ester group is bound to a different carbon atom within the same molecule;
• or
• when n is 2 to 10:
• p is 3, 4, 5 or 6;
• preferably 3, 4 or 5;
• preferably 3 or 4;
• or
• when n is 11 to 70:
• p is 2, 3, 4, 5 or 6;
• preferably 2, 3, 4 or 5;
• preferably 2, 3 or 4;
• or A means A2 and
• A2 is a residue of an amino acid or of a sequence of amino acids resp. of a protein or of a polypeptide, preferably a residue of the superfamily of Transforming Growth Factor beta (TGF-β);
• or a residue of a specific drug molecule, wherein each residue A2 carries p phosphonic acid groups, and
• p is 1 to 6, preferably 1, 2, 3 or 4, preferably 1, 2, or 3, when A2 is a residue of an amino acid or of a sequence of amino acids resp. of a protein or of a polypeptide;
• or
• p is 1 or 3-6, preferably 1, when A2 is a residue of a specific drug molecule originally not bearing any phosphonate group, optionally falling under the definition given for A1.